Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H18O4 |
Molecular Weight | 262.301 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@H](C)[C@]3([H])C=CC(=O)[C@@]3(C)[C@@H](O)[C@]1([H])C(=C)C(=O)O2
InChI
InChIKey=ZVLOPMNVFLSSAA-XEPQRQSNSA-N
InChI=1S/C15H18O4/c1-7-6-10-12(8(2)14(18)19-10)13(17)15(3)9(7)4-5-11(15)16/h4-5,7,9-10,12-13,17H,2,6H2,1,3H3/t7-,9+,10-,12-,13+,15+/m1/s1
Molecular Formula | C15H18O4 |
Molecular Weight | 262.301 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of homodimerization of Toll-like receptor 4 by curcumin. | 2006 Jun 28 |
|
Inhibition of Nod2 signaling and target gene expression by curcumin. | 2008 Jul |
|
Overexpression of HO-1 protects against TNF-alpha-mediated airway inflammation by down-regulation of TNFR1-dependent oxidative stress. | 2009 Aug |
|
Helenalin-induced apoptosis is dependent on production of reactive oxygen species and independent of induction of endoplasmic reticulum stress in renal cell carcinoma. | 2013 Mar |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:44:05 GMT 2023
by
admin
on
Fri Dec 15 19:44:05 GMT 2023
|
Record UNII |
4GUY9L896T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3490
Created by
admin on Fri Dec 15 19:44:05 GMT 2023 , Edited by admin on Fri Dec 15 19:44:05 GMT 2023
|
PRIMARY | |||
|
23205
Created by
admin on Fri Dec 15 19:44:05 GMT 2023 , Edited by admin on Fri Dec 15 19:44:05 GMT 2023
|
PRIMARY | |||
|
HELENALIN
Created by
admin on Fri Dec 15 19:44:05 GMT 2023 , Edited by admin on Fri Dec 15 19:44:05 GMT 2023
|
PRIMARY | |||
|
C001329
Created by
admin on Fri Dec 15 19:44:05 GMT 2023 , Edited by admin on Fri Dec 15 19:44:05 GMT 2023
|
PRIMARY | |||
|
85236
Created by
admin on Fri Dec 15 19:44:05 GMT 2023 , Edited by admin on Fri Dec 15 19:44:05 GMT 2023
|
PRIMARY | |||
|
DTXSID50217868
Created by
admin on Fri Dec 15 19:44:05 GMT 2023 , Edited by admin on Fri Dec 15 19:44:05 GMT 2023
|
PRIMARY | |||
|
4GUY9L896T
Created by
admin on Fri Dec 15 19:44:05 GMT 2023 , Edited by admin on Fri Dec 15 19:44:05 GMT 2023
|
PRIMARY | |||
|
6754-13-8
Created by
admin on Fri Dec 15 19:44:05 GMT 2023 , Edited by admin on Fri Dec 15 19:44:05 GMT 2023
|
PRIMARY | |||
|
m5931
Created by
admin on Fri Dec 15 19:44:05 GMT 2023 , Edited by admin on Fri Dec 15 19:44:05 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Helenalin selectively alkylates p65 subunit at
Cys38 [27, 63]. Formation of this covalent bond sterically
prevents the p50/p65 heterodimer from binding to DNA and therefore inhibits its transcriptional activation.
|
||
|
TARGET -> INHIBITOR |
|
||
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
|
||
|
TARGET -> INHIBITOR |
Helenalin binds to Cys445 of telomerase
in the Michael-type addition reaction, disturbing recognition of the telomere DNA at the telomerase active site and causing suppression of the enzyme activity.
|
||
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
|